<DOC>
	<DOC>NCT02806232</DOC>
	<brief_summary>The Phase II study consisting of two parts, part 1 is open label, randomized, controlled and exploratory dose finding in children aged between 2 and 6 years infected with S. mansoni. Part 2a investigates efficacy and safety in children 3 months to 2 years in an age-de-escalating design and part 2b is optional and investigates the efficacy of L-PZQ in S. hematobium.</brief_summary>
	<brief_title>An Open Label Dose Finding Safety and Efficacy in Children and Infants Infected With Schistosomiasis (S.Mansoni)</brief_title>
	<detailed_description />
	<mesh_term>Schistosomiasis</mesh_term>
	<mesh_term>Praziquantel</mesh_term>
	<criteria>Male and female children aged 2 to 6 years (Part 1 and 2b) and 3 to 24 months (Part 2a) S. mansoni positive diagnosis in Part 1 and Part 2a, defined as positive egg counts in stool (greater than [&gt;]1 egg/1 occasion) according to World Health Organization (WHO) classification : light (199 eggs per gram of faeces), moderate (100399 eggs per gram of faeces) and heavy (greater than or equal to [&gt;=]400 eggs per gram of faeces) infections S. haematobium positive diagnosis in Part 2b, defined as positive egg counts in urine (&gt;2 eggs/10 milliliter [ml] urine) according to WHO classification : light ( less than [&lt;]50 eggs/10 ml of urine) and heavy (&gt;=50 eggs/10 ml of urine) infections Minimum weight of 8.0 kg in 2 to 6yearold children and of 4.0 kg in 3 to 24month infants â€¢ Parents/legal guardian's ability to communicate well with the Investigator, to understand the protocol requirements and restrictions, and willing their children to comply with the requirements of the entire trial, i.e. To be examined by a study physician at screening and 1421 days after treatment To provide stool and urine samples at screening, 24 hours and 8 days after treatment, as well as 1421 days after treatment To provide finger prick blood samples for Pharmacokinetics (PK) studies and blood samples for safety assessments Treatment in the 4 weeks prior to study screening with Praziquantel (PZQ) , other antihelminthic, antimalarial or antiretroviral compounds or any other medication that might affect the PK of PZQ such as certain antiepileptics (e.g., carbamazepine or phenytoin), glucocorticosteroids (e.g., dexamethasone), chloroquine, rifampicin or cimetidine For children being breast fed, treatment of the mothers/wet nurses with PZQ in the 3 days prior to administration of Investigational medicinal product Previous history of adverse reactions associated with PZQ treatment History of acute or severe chronic disease including hepatosplenic schistosomiasis Fever defined as temperature above 38.0 degree centigrade Debilitating illnesses such as tuberculosis, malnutrition, etc. Mixed S. haematobium and S. mansoni infections Findings in the clinical examination of schistosomeinfected children participating in the study as performed by the study clinician on the treatment day, that in the opinion of the Investigator constitutes a risk or a contraindication for the participation of the subject in the study or that could interfere with the study objectives, conduct or evaluation Unlikelihood to comply with the protocol requirements, instructions and trialrelated restrictions, e.g., uncooperative attitude, inability to return for followup visits, and improbability of completing the trial</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Praziquantel ODT formulation</keyword>
	<keyword>Biltricide</keyword>
</DOC>